Unlearn Appoints AstraZeneca’s Chief Medical Officer Ann E. Taylor, M.D. to Board of Directors

Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to enable smaller, faster clinical trials, today announced the appointment of Ann E. Taylor, M.D. to the company’s Board of Directors. Dr. Taylor currently serves as Chief Medical Officer at AstraZeneca and is a leading expert in clinical development.

“We are honored to welcome Dr. Taylor to the Unlearn team. Her deep expertise in clinical development and leadership in the pharmaceutical industry will be invaluable as we work towards expanding our clinical trial collaborations globally,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “Unlearn is in an exciting phase of growth and with the support of forward-thinking executives like Dr. Taylor, we are poised to expand the use of our Digital Twins and help accelerate clinical trials and the delivery of new medicines to patients.”

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials


Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™


Success is never a straight line—reflecting on our EMA draft qualification opinion

On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.